X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.

The US Food and Drug Administration (FDA) classified this as a Class 1 recall, meaning the product posed a serious health ...

An estimated 15 million Americans have food allergies, which result in 30,000 ED visits and 150–200 fatalities annually ...